

Dermatology Medications

Reference Number: F4762
Date of Response: 26/08/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

How many patients were treated in June 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo) **0 Patients****
- Baricitinib (Olumiant) * **Patients**
- Bimekizumab (Bimzelx) **0 Patients**
- Brodalumab (Kyntheum) * **Patients**
- Dupilumab (Dupixent) **70 Patients**
- Ixekizumab (Taltz) **12 Patients**
- Risankizumab (Skyrizi) * **Patients**
- Guselkumab (Tremfya) **15 Patients**
- Secukinumab (Cosentyx) **23 Patients**
- Tildrakizumab (Ilumetri) **5 Patients**
- Tralokinumab (Adtralza) **0 Patients****
- Upadacitinib (Rinvoq) * **Patient**
- Ustekinumab (Stelara) **19 Patients**

[*] Low value suppressed to protect patient identity - ≤5.

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

[] Pharmacy have confirmed Trust yet to use either of these two medications**